Your browser doesn't support javascript.
loading
Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma.
Abeykoon, Jithma P; Vaxman, Julia; Patel, Sanjay V; Kumar, Shaji; Malave, Gabriella C; Young, Kimberly S; Ailawadhi, Sikander; Larsen, Jeremy T; Dispenzieri, Angela; Muchtar, Eli; Gonsalves, Wilson I; Kourelis, Taxiarchis; Leung, Nelson; Warsame, Rahma; Go, Ronald S; Bergsagel, Leif; Lacy, Martha Q; Rajkumar, S Vincent; Gertz, Morie A; Kapoor, Prashant.
Afiliação
  • Abeykoon JP; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Vaxman J; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Patel SV; Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
  • Kumar S; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Malave GC; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Young KS; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Ailawadhi S; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
  • Larsen JT; Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA.
  • Dispenzieri A; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Muchtar E; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Gonsalves WI; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Kourelis T; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Leung N; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Warsame R; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Go RS; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Bergsagel L; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Lacy MQ; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Rajkumar SV; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Gertz MA; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Kapoor P; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Br J Haematol ; 199(1): 95-99, 2022 10.
Article em En | MEDLINE | ID: mdl-35694818
ABSTRACT
Belantamab mafodotin (BLMF) is a B-cell maturation antigen-directed antibody-drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF-induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity-related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval 0.2-not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoconjugados / Mieloma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoconjugados / Mieloma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article